
Yupelri
My Prescription
Payment
Select pharmacy




$57.61
Print or send this coupon to your phone
About Yupelri
Drug Details
Revefenacin, marketed under the brand name Yupelri, is a medication designed for the long-term management of chronic obstructive pulmonary disease (COPD) in adults. It belongs to a group of drugs known as long-acting muscarinic antagonists (LAMAs), which function by relaxing the muscles around the airways, thereby widening them and making breathing easier. This medicine is intended to be used regularly through inhalation with a nebulizer machine, typically once a day, to help reduce and prevent symptoms like shortness of breath, coughing, and wheezing. It's important to note that Revefenacin does not provide immediate relief for sudden breathing issues; in such cases, a quick-relief inhaler as directed by a healthcare provider should be used. Some common side effects may include headaches and cough. Currently, there is no generic version of this medication available.
Price history for Yupelri
1 Plas Cont, 3ML of 175MCG/3ML
Average retail price for Yupelri
Average SaveHealth price for Yupelri
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Yupelri dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 3ML of 175MCG/3ML | 1 Plas Cont | $62.59 | $62.59 |
| 3ML of 175MCG/3ML | 2 Plas Conts | $120.18 | $60.09 |
| 3ML of 175MCG/3ML | 3 Plas Conts | $174.02 | $58.01 |
Yupelri FAQs
Yupelri and albuterol are not the same. Yupelri contains the active ingredient revefenacin, which is a long-acting muscarinic antagonist (LAMA) used for maintenance treatment of chronic obstructive pulmonary disease (COPD). Albuterol, on the other hand, is a short-acting beta-agonist (SABA) used for quick relief of asthma symptoms and COPD exacerbations. They have different mechanisms of action and are used for different purposes in respiratory care.
Yupelri and Spiriva are not the same medication, although both are used to treat chronic obstructive pulmonary disease (COPD). Yupelri contains the active ingredient revefenacin, while Spiriva contains tiotropium. They belong to different classes of bronchodilators and work in slightly different ways to help open the airways and make breathing easier.
Yupelri (revefenacin) is a medication used to help relax and open the airways in the lungs, making it easier to breathe. It is typically prescribed for individuals with chronic obstructive pulmonary disease (COPD) to improve lung function and reduce symptoms such as shortness of breath.
One of the newer medications for COPD that can be administered via a nebulizer is revefenacin, marketed under the brand name Yupelri. It is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of COPD. It is important for patients to consult with their healthcare provider to determine the most appropriate treatment for their condition.
A healthcare provider may consider alternatives such as other long-acting muscarinic antagonists (LAMAs) or bronchodilators for managing chronic obstructive pulmonary disease (COPD). Options might include tiotropium (Spiriva), aclidinium (Tudorza), or glycopyrrolate (Seebri). It is important for the patient to consult with their healthcare provider to determine the most appropriate medication based on their specific condition and medical history.